No connection

Search Results

BNGO vs NXL

BNGO
Bionano Genomics, Inc.
BEARISH
Price
$1.15
Market Cap
$11.7M
Sector
Healthcare
AI Confidence
85%
NXL
Nexalin Technology, Inc.
BEARISH
Price
$0.51
Market Cap
$10.5M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
BNGO
--
NXL
--
Forward P/E
BNGO
-0.46
NXL
-1.64
P/B Ratio
BNGO
0.22
NXL
2.61
P/S Ratio
BNGO
0.39
NXL
34.73
EV/EBITDA
BNGO
-0.45
NXL
-0.81

Profitability

Gross Margin
BNGO
45.97%
NXL
79.65%
Operating Margin
BNGO
-115.89%
NXL
-1403.86%
Profit Margin
BNGO
-134.36%
NXL
0.0%
ROE
BNGO
-78.22%
NXL
-221.5%
ROA
BNGO
-19.31%
NXL
-118.41%

Growth

Revenue Growth
BNGO
21.3%
NXL
532.5%
Earnings Growth
BNGO
--
NXL
--

Financial Health

Debt/Equity
BNGO
0.35
NXL
--
Current Ratio
BNGO
2.12
NXL
4.84
Quick Ratio
BNGO
1.14
NXL
4.29

Dividends

Dividend Yield
BNGO
--
NXL
--
Payout Ratio
BNGO
0.0%
NXL
0.0%

AI Verdict

BNGO BEARISH

BNGO exhibits severe financial distress despite modest revenue growth, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics (e.g., -134.36% profit margin, -78.22% ROE) signal deep operational inefficiencies and high risk of insolvency. Although the stock shows a recent technical uptick and strong earnings surprise history, these are overshadowed by deteriorating fundamentals, massive losses, and a 5-year price decline of 100%. The lack of a Graham Number and intrinsic value estimate further underscores the absence of a reliable valuation anchor. Analysts have a target price of $5.50, but this is not supported by current fundamentals and appears speculative.

Strengths
21.30% year-over-year revenue growth indicates market traction in a high-growth sector
Gross margin of 45.97% suggests strong pricing power and cost control in product delivery
Recent quarterly earnings surprises (average +42.66%) show potential for better-than-expected execution
Risks
Piotroski F-Score of 1/9 is critically low, signaling severe financial deterioration and poor operational efficiency
Negative ROE (-78.22%) and ROA (-19.31%) reflect deep capital inefficiency and sustained losses
Profit margin of -134.36% and operating margin of -115.89% indicate unsustainable business model at current scale
NXL BEARISH

NXL exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company shows explosive year-over-year revenue growth of 532.50%, this is completely offset by a catastrophic operating margin of -1403.86% and negative ROE of -221.50%. The stock is currently trading at an exorbitant Price/Sales ratio of 34.73, which is unsustainable given the lack of profitability. Despite a recent short-term price bounce and a single analyst's 'buy' rating, the underlying deterministic data suggests a high risk of capital impairment.

Strengths
Exceptional YoY revenue growth (532.50%)
Strong gross margins (79.65%) indicating product value
Healthy short-term liquidity (Current Ratio 4.84)
Risks
Extreme operational inefficiency (Operating Margin -1403.86%)
Critical financial health failure (Piotroski F-Score 1/9)
Severe valuation disconnect (P/S Ratio 34.73)

Compare Another Pair

BNGO vs NXL: Head-to-Head Comparison

This page compares Bionano Genomics, Inc. (BNGO) and Nexalin Technology, Inc. (NXL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile